The latest-generation Lightning Flash CAVT offering includes significant upgrades, advancing Penumbra’s venous thromboembolism (VTE) platform, the company says.

Penumbra — which is set to be acquired by Boston Scientific for $14.5 billion — said it engineered its latest Flash 3.0 algorithm for the rapid removal of pulmonary and venous thrombus. It designed the algorithm for enhanced clot detection capabilities with increased sensitivity to thrombus and blood.